It is estimated to enroll 1210 stage IIA–IIIB (AJCC 8th TNM stage) participants with NSCLC without EGFR mutations or ALK rearrangements (applicable only to patients with nonsquamous tumors). The gene discussed is ALK; the disease is non-small cell lung carcinoma.